Novel Secondary Hormonal Therapies for Prostate Cancer 2015

Posted by Erik P. Castle, MD, FACS | Mar 2016

Dr. Erik P. Castle spoke at the 24th annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 14, 2015 on “Novel Secondary Hormonal Therapies for Prostate Cancer.”

Presentation

Keywords novel secondary hormonal therapies, prostate cancer

How to cite: Castle, Erik P. “Novel Secondary Hormonal Therapies for Prostate Cancer” Grand Rounds in Urology. November 14, 2015. Accessed Apr 2024. https://dev.grandroundsinurology.com/prostate-cancer-erik-p-castle-novel-secondary-hormonal-therapies-for-prostate-cancer-2015/.

About The Author

Erik P. Castle, MD, FACS

Dr. Erik P. Castle is a Professor of Urology at the Mayo Clinic College of Medicine. His surgical expertise includes minimally invasive urologic oncology, including robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He has demonstrated many of these procedures internationally, as he pioneered robot cystectomy as well as robot RPLND. He directs the International Laparoscopic Nephrectomy Program in Mexico on behalf of the American Urologic Association (AUA), and also serves on several committees and guideline panels within the American Urologic Association. He is on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN) as well. Dr. Castle’s research interests include prostate cancer, bladder cancer, and kidney cancer. He is the Director of the Desert Mountain Care Prostate Cancer Research Fund and is the principal investigator of his lab housed at the Mayo Clinic Collaborative Research Building. His basic science research is focused on novel secondary hormonal therapies of prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also directs the prospectively collected genitourinary biorepository at Mayo Clinic Arizona, which houses over 40,000 specimens.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Novel Secondary Hormonal Therapies for Prostate Cancer 2015

About The Author

Erik P. Castle, MD, FACS

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Novel Secondary Hormonal Therapies for Prostate Cancer 2015

About The Author

Erik P. Castle, MD, FACS

Related Posts

Advanced Disease: A Real Need for Understanding and Shared Care

Point Counterpoint: The Optimal Nadir T Level on ADT Is <20mg/mL

Transperineal Prostate Biopsy Under Local Anesthesia: Systematic and MRI-Ultrasound Fusion Biopsy

Recognizing and Managing the Side Effects of Androgen Deprivation Therapy

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses